Patents by Inventor Andre A. Kiryanov

Andre A. Kiryanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF
    Publication number: 20240309016
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 15, 2024
    Publication date: September 19, 2024
    Inventors: Mitsunori KONO, Yusuke SASAKI, Yuya OGURO, Zenichi IKEDA, Osamu KUBO, Masaki SETO, Toru YAMASHITA, Makoto KAMATA, Kenjiro SATO, Matthew Thomas REYNOLDS, Kazuaki TAKAMI, Asato KINA, Takafumi YUKAWA, Minoru NAKAMURA, Taku KAMEI, Hiroyuki KAKEI, Fumie YAMAGUCHI, Tomohiro OHASHI, Keiko KAKEGAWA, Takuto KOJIMA, Florian PÜNNER, Masataka MURAKAMI, Takahiko TANIGUCHI, Tatsuki KOIKE, Yuichi KAJITA, Yuhei MIYANOHANA, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Yasushi HATTORI, Eiji KIMURA, Martin Alexander PAWLICZEK, Marilena PIRA, Shuhei IKEDA, Noriyuki TEZUKA, Yoshikazu WATANABE, Kevin CURRAN, Nicolle DOERING, Maria HOPKINS, Ben JOHNSON, Andre KIRYANOV, Jon LAM, Sean MURPHY, Natasha O'ROURKE, Holly REICHARD, Paul TANIS, Yunlong ZHANG
  • Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
    Patent number: 11426397
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 30, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6
    Publication number: 20200375969
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Application
    Filed: March 26, 2018
    Publication date: December 3, 2020
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES
    Publication number: 20200277262
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R3, R4, R5, R6, R7, R8, R9, X1 and X2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with PHD.
    Type: Application
    Filed: September 24, 2018
    Publication date: September 3, 2020
    Inventors: Benjamin Jones, Andre Kiryanov, Jon Kuehler, Marion Lanier, Sean Murphy, Feng Zhou
  • 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD
    Patent number: 10407409
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    Publication number: 20180186772
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD
    Patent number: 9944626
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: April 17, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    Publication number: 20170275271
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD
    Patent number: 9708296
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: July 18, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    Publication number: 20160251337
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD
    Patent number: 9345713
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)
    Patent number: 9187497
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R31, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 17, 2015
    Assignee: Takeda Phamaceutical Company Limited
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    Publication number: 20150224113
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD
    Patent number: 9040522
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: May 26, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
    Publication number: 20150031652
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 29, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    Publication number: 20140296200
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Substituted pyrido[2,3-b]pyrazines
    Patent number: 8822470
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, and X, are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: September 2, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
    Publication number: 20130274239
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Application
    Filed: May 8, 2013
    Publication date: October 17, 2013
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. A. Kiryanov
  • Poly (ADP-ribose) polymerase (PARP) inhibitors
    Patent number: 8541417
    Abstract: Compounds of the following formula are provided for use with PARP: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: September 24, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Anthony R. Gangloff, Andre A. Kiryanov
  • Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine
    Patent number: 8450323
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R6, R7, R12, X, and q are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: May 28, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov